The FIREFLY-2 Trial
FIREFLY-2 is a phase 3, 2-arm, randomized, multicenter, open-label study to evaluate the
efficacy, safety, and tolerability of monotherapy tovorafenib, an investigational, oral, pan-RAF inhibitor versus standard of care (SoC) chemotherapy in pediatric patients with RAF-altered low-grade glioma requiring front-line systemic therapy
Sponsor: Day One Biopharmaceuticals, Inc.
Collaborator: SIOPe Brain Tumor Group LOGGIC Consortium (LOGGIC)
Status: Now enrolling patients
Condition: Low-grade glioma harboring RAF alterations
Phase: 3
NCT Number: NCT05566795
EudraCT Number: 2022-001363-27
Other Study ID Numbers: LOGGIC/FIREFLY-2
Discover more details and enrollment information about FIREFLY-2
VIEW FIREFLY-2 TRIAL
Read a plain language summary (PLS) of the recent clinical trial results from this study
CLICK TO VIEW